Peter Bruno,

Peter Bruno, PhD, received his undergraduate training at University of California, San Diego, where he earned his degree in Molecular Biology summa cum laude. At the Massachusetts Institute of Technology, he received his PhD in Biology under the mentorship of Dr. Michael Hemann where he uncovered unexpected mechanisms of action for new and old anti-cancer agents, nanoparticles, and drug combinations using RNAi and other functional genetic approaches. Starting in 2016 he began his postdoctoral work with Dr. Stephen J. Elledge of Harvard Medical School and Brigham and Women’s Hospital. There he sought to use genetics instead of biochemical approaches to improve the characterization of peptides that bind MHC. The tool he developed, EpiScan, enables a dramatic improvement in the scale and specificity of MHC ligand determination.